183 related articles for article (PubMed ID: 35838992)
21. DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers.
Katzendorn O; Peters I; Dubrowinskaja N; Tezval H; Tabrizi PF; von Klot CA; Hennenlotter J; Lafos M; Kuczyk MA; Serth J
BMC Cancer; 2021 Apr; 21(1):444. PubMed ID: 33882870
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM
Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320
[TBL] [Abstract][Full Text] [Related]
24. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.
Peters I; Rehmet K; Wilke N; Kuczyk MA; Hennenlotter J; Eilers T; Machtens S; Jonas U; Serth J
Mol Cancer; 2007 Jul; 6():49. PubMed ID: 17634119
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
26. LZTS2 promoter hypermethylation: a potential biomarker for the diagnosis and prognosis of laryngeal squamous cell carcinoma.
Shen Z; Lin L; Cao B; Zhou C; Hao W; Ye D
World J Surg Oncol; 2018 Mar; 16(1):42. PubMed ID: 29499699
[TBL] [Abstract][Full Text] [Related]
27. Silencing of tumor-suppressive NR_023387 in renal cell carcinoma via promoter hypermethylation and HNF4A deficiency.
Zhou H; Guo L; Yao W; Shi R; Yu G; Xu H; Ye Z
J Cell Physiol; 2020 Mar; 235(3):2113-2128. PubMed ID: 31432508
[TBL] [Abstract][Full Text] [Related]
28. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival.
Hu CY; Mohtat D; Yu Y; Ko YA; Shenoy N; Bhattacharya S; Izquierdo MC; Park AS; Giricz O; Vallumsetla N; Gundabolu K; Ware K; Bhagat TD; Suzuki M; Pullman J; Liu XS; Greally JM; Susztak K; Verma A
Clin Cancer Res; 2014 Aug; 20(16):4349-60. PubMed ID: 24916699
[TBL] [Abstract][Full Text] [Related]
29. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Köllermann J; Miller K; Schrader M
Clin Cancer Res; 2006 Sep; 12(17):5040-6. PubMed ID: 16951219
[TBL] [Abstract][Full Text] [Related]
30. Recurrent transcriptional loss of the PCDH17 tumor suppressor in laryngeal squamous cell carcinoma is partially mediated by aberrant promoter DNA methylation.
Byzia E; Soloch N; Bodnar M; Szaumkessel M; Kiwerska K; Kostrzewska-Poczekaj M; Jarmuz-Szymczak M; Szylberg L; Wierzbicka M; Bartochowska A; Kalinowicz E; Grenman R; Szyfter K; Marszalek A; Giefing M
Mol Carcinog; 2018 Jul; 57(7):878-885. PubMed ID: 29566279
[TBL] [Abstract][Full Text] [Related]
31. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
32. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
Costa VL; Henrique R; Ribeiro FR; Pinto M; Oliveira J; Lobo F; Teixeira MR; Jerónimo C
BMC Cancer; 2007 Jul; 7():133. PubMed ID: 17645803
[TBL] [Abstract][Full Text] [Related]
33. Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy.
Lin YL; Deng QK; Wang YH; Fu XL; Ma JG; Li WP
Med Sci Monit; 2015 Dec; 21():3955-690. PubMed ID: 26683656
[TBL] [Abstract][Full Text] [Related]
34. Methylation of RASSF1A gene promoter and the correlation with DNMT1 expression that may contribute to esophageal squamous cell carcinoma.
Du Z; Ma K; Sun X; Li A; Wang H; Zhang L; Lin F; Feng X; Song J
World J Surg Oncol; 2015 Apr; 13():141. PubMed ID: 25886188
[TBL] [Abstract][Full Text] [Related]
35. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.
Luo ZG; Li ZG; Gui SL; Chi BJ; Ma JG
J Int Med Res; 2014 Feb; 42(1):35-41. PubMed ID: 24366498
[TBL] [Abstract][Full Text] [Related]
36. Decreased expression of RASSF1A tumor suppressor gene is associated with worse prognosis in clear cell renal cell carcinoma.
Klacz J; Wierzbicki PM; Wronska A; Rybarczyk A; Stanislawowski M; Slebioda T; Olejniczak A; Matuszewski M; Kmiec Z
Int J Oncol; 2016 Jan; 48(1):55-66. PubMed ID: 26648328
[TBL] [Abstract][Full Text] [Related]
37. Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.
Deckers IA; Schouten LJ; Van Neste L; van Vlodrop IJ; Soetekouw PM; Baldewijns MM; Jeschke J; Ahuja N; Herman JG; van den Brandt PA; van Engeland M
Clin Cancer Res; 2015 Aug; 21(15):3492-500. PubMed ID: 25904753
[TBL] [Abstract][Full Text] [Related]
38. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S
Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472
[TBL] [Abstract][Full Text] [Related]
39. Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer.
Fu D; Ren C; Tan H; Wei J; Zhu Y; He C; Shao W; Zhang J
Medicine (Baltimore); 2015 Mar; 94(11):e637. PubMed ID: 25789956
[TBL] [Abstract][Full Text] [Related]
40. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
Breault JE; Shiina H; Igawa M; Ribeiro-Filho LA; Deguchi M; Enokida H; Urakami S; Terashima M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):557-64. PubMed ID: 15701841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]